- Home
- YQ vs ICU Comparison
YQ vs ICU Comparison
Compare YQ & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- ICU
- Stock Information
- Founded
- YQ 2012
- ICU 2018
- Country
- YQ China
- ICU United States
- Employees
- YQ N/A
- ICU N/A
- Industry
- YQ Other Consumer Services
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- ICU Health Care
- Exchange
- YQ Nasdaq
- ICU Nasdaq
- Market Cap
- YQ 19.4M
- ICU 20.3M
- IPO Year
- YQ 2020
- ICU N/A
- Fundamental
- Price
- YQ $1.97
- ICU $0.80
- Analyst Decision
- YQ
- ICU
- Analyst Count
- YQ 0
- ICU 0
- Target Price
- YQ N/A
- ICU N/A
- AVG Volume (30 Days)
- YQ 20.8K
- ICU 1.9M
- Earning Date
- YQ 09-03-2025
- ICU 08-13-2025
- Dividend Yield
- YQ N/A
- ICU N/A
- EPS Growth
- YQ N/A
- ICU N/A
- EPS
- YQ N/A
- ICU N/A
- Revenue
- YQ $25,546,613.00
- ICU $766,000.00
- Revenue This Year
- YQ N/A
- ICU $754.07
- Revenue Next Year
- YQ N/A
- ICU $100.09
- P/E Ratio
- YQ N/A
- ICU N/A
- Revenue Growth
- YQ N/A
- ICU N/A
- 52 Week Low
- YQ $1.26
- ICU $0.31
- 52 Week High
- YQ $3.19
- ICU $6.65
- Technical
- Relative Strength Index (RSI)
- YQ 46.13
- ICU 53.18
- Support Level
- YQ $1.94
- ICU $0.76
- Resistance Level
- YQ $2.02
- ICU $0.81
- Average True Range (ATR)
- YQ 0.07
- ICU 0.07
- MACD
- YQ 0.01
- ICU 0.01
- Stochastic Oscillator
- YQ 75.00
- ICU 53.69
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.